DC-GALLUP
25.6.2024 06:02:29 CEST | Business Wire | Press release
In 2023, Ukraine was engulfed in war, while a new clash erupted between Israel and Hamas in the European sphere of influence. The Gallup Global Emotions 2024 report reveals the emotional toll of these conflicts.
The report offers a snapshot of Gallup’s latest measurements of people’s positive and negative daily experiences. The findings are based on nearly 146,000 interviews with adults in 142 countries and areas in 2023. While global negative emotions dipped for the first time in a decade and positive emotions rebounded to their pre-pandemic highs, many of the world’s conflict zones remained bleak.
After Oct. 7 Attacks, Israel Vaulted to Top 10 in Negative Emotions
Israel, surveyed by Gallup two weeks after the Oct. 7 Hamas attacks, made the top 10 list of countries with the worst Negative Experience Index scores for the first time, at 47. In 2022, Israel ranked among the countries with the lowest scores in the world on this index.
Fueling this low score, Israelis saw massive increases in feelings of sadness (up 39 percentage points to 51%), stress (up 38 points to 62%), anger (up 23 points to 36%) and worry (up 37 points to 67%).
Ukrainian Negative Emotions Remained at Post-Invasion Record Highs
As Ukraine continued to fend off Russian offensives within its borders in 2023, Ukrainians reported record-tying levels of sadness (39%), stress (32%), anger (22%) and worry (53%).
Negative Emotions Dropped in Azerbaijan After Ceasefire
Following the signing of the Nagorno-Karabakh ceasefire agreement, Azerbaijan led the world in declining stress levels — dropping from 40% to 14% in the span of a year. In addition to less stress, Azerbaijanis reported significant decreases in feelings of daily anger, worry and sadness.
About the Indexes
Gallup’s Positive and Negative Experience Indexes measure life’s intangibles — feelings and emotions — that traditional economic indicators such as GDP were never intended to capture. Each index provides a real-time snapshot of people’s daily experiences, offering leaders insights into the health of their societies that they cannot gather from economic measures alone.
Negative Experience Index Dipped in 2023
On a global level, Gallup’s Negative Experience Index declined for the first time since 2014. All five negative emotions that make up the index fell between 2022 and 2023, but stress levels dropped the most. Thirty-seven percent of the world felt stressed in 2023, down three points from the previous year but well above where it was a decade ago (33%) and the years before that.
Positive Experience Index Rebounded Post-Pandemic
Further reinforcing that 2023 was a better year for the world’s emotional health, positive experiences rebounded to their pre-pandemic levels, completing the recovery that started in 2022.
People younger than 30 continued to be the most positive of all age groups. Further, their positivity rebounded faster, with emotions bouncing back a year earlier than their older peers. Most of the improvement on the index in 2023 took place among those aged 30 and older.
About Gallup
Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.
About the Gallup World Poll
The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 99% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries. The Gallup World Poll is used to measure and track progress on several U.N. sustainable development goals and is the official statistic for work and life for more than 55 indexes and metrics associated with the most important aspects of individuals’ lives, their communities and their countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624491362/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
